Prospective Multiomic Analysis in Small-Cell Lung Cancer

StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened
    • Site details revised
    • Study description expanded, about 3 words
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This is an observational study to collects blood samples and tumor tissue from adults with relapsed small-cell lung cancer (SCLC) receiving standard of care commercial DLL3 T cell engager. The goal of the study is to understand the changes in tumor markers over time and examine whether these changes are associated with clinical outcomes. Participants will provide blood samples and, when clinically feasible, tumor tissue during routine care visits, treatment, and imaging assessments. The study does not assign cancer treatment.
Trial Details
NCT Number NCT07795411
Lead Sponsor Ohio State University Comprehensive Cancer Center
Collaborators: Genentech, Inc.
Conditions
(from sponsor)		 Small Cell Cancer Of The Lung, Small Cell Lung Cancer ( SCLC ), Lung Cancer, Small-Cell Lung Cancer (SCLC)
Related terms Lung Neoplasms, Small Cell Lung Carcinoma
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov